Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia

This article was originally published in The Pink Sheet Daily

Executive Summary

After additional cardiovascular events are seen, European regulators move to pull sibutramine, while FDA asks for a contraindication.

You may also be interested in...



Same Data, Same Day, Different Decision: FDA, EMA On Roche's Protease Inhibitor Invirase

FDA goes for a new warning and a MedGuide; EMA calls for a lower starting dose.

Same Data, Same Day, Different Decision: FDA, EMA On Roche's Protease Inhibitor Invirase

FDA goes for a new warning and a MedGuide; EMA calls for a lower starting dose.

Korea FDA Withdraws Abbott's Meridia; Criticism Increases On Agency's Dependence On U.S. FDA For Safety

SEOUL - Korea FDA banned new prescriptions for Abbott's obesity product sibutramine while it recommended "voluntary withdrawal" of the product following similar actions in the U.S. and Europe, drawing criticism that KFDA is too reliant on foreign agencies for monitoring drug safety

Related Content

Topics

UsernamePublicRestriction

Register

PS070137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel